Bright Minds Biosciences Inc.: updates and filings

DRUGNASDAQHealthcare · Pharmaceutical Preparations

Price

$20.40

November 20, 2026Market cap $140M

What Ploutos Investor adds for Bright Minds Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from FY2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Dec 23, 2025 latest annual
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 2, 2026Current report (foreign company)
    Form6-K
  • Oct 2, 2026Current report (foreign company)
    Form6-K
  • Oct 1, 2026Current report (foreign company)
    Form6-K
  • Aug 17, 2026Current report (foreign company)
    Form6-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Shares registered for employees
    FormS-8
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 2, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jun 3, 2026Current report (foreign company)
    Form6-K
  • Jun 2, 2026Current report (foreign company)
    Form6-K
  • May 28, 2026Current report (foreign company)
    Form6-K
  • May 20, 2026Current report (foreign company)
    Form6-K
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 30, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 13, 2026Current report (foreign company)
    Form6-K
  • Feb 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jan 9, 2026Current report (foreign company)
    Form6-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 6, 2020.

The full analysis

What do Bright Minds Biosciences's filings show?

The filings are where every one of Bright Minds Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.